NCT04009915 (VOLCANO) is a Phase 3 clinical trial of VATS in Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT04009915?

NCT04009915 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT04009915?

Interventions in NCT04009915: VATS, Open surgery.

What condition does NCT04009915 study?

NCT04009915 studies Lung Cancer, Surgery.

Is NCT04009915 still recruiting?

NCT04009915 is currently status unknown. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT04009915: VOLCANO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VATS VS. Open Thoracic Surgery for Stage II - III Lung Cancer

Status unknown Phase 3 Last updated 9 May 2022

What this trial tests

Phase 3 trial testing VATS in Lung Cancer in 200 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
30 December 2024

30 December 2025

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 June 2019
Primary completion	30 December 2024
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

VATS
Open surgery

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Surgery — all drugs for Surgery →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

18 and older, any sex, with Lung Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For patients with stage I lung cancer, the NCCN guidelines point out that if the patient has no contraindications for anatomy and surgery, as long as it does not violate the standard of tumor treatment and the principle of thoracic surgery, it is highly recommended of VATS or minimally invasive surgery. Although previous papers seem to have obvious advantages, there is a lack of clinical prospective data from patients with stage II-III lung cancer, and especially in the prevalence of uniportal VATS, there is still no objective analysis of this hypothesis. Therefore, the investigators plan to conduct a randomized, prospective study to compare perioperative complications, postoperative pain, life quality, lung function recovery, tumor-free survival rate, etc., in lobectomy for stage II-III lung cancer patients with VATS and thoracotomy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Randomized controlled trials in lung cancer surgery: How are we doing?
Wong LY, Li Y, Elliott IA, Backhus LM, et al · · 2024 · cited 1× · PMID 38690441 · DOI 10.1016/j.xjon.2024.01.008

Verify or expand the search:

Other trials of VATS

Trials testing the same drug.

NCT03786003 — ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) · NA · recruiting
NCT04755478 — LUS to Assess Lung Injury After Lung Lobectomy · unknown
NCT04805723 — Effects of Surgery Types in Patients With Pulmonary Nodules · NA · completed
NCT03083080 — VATS Block for Uniportal Video-assisted Thoracoscopic Surgery · NA · unknown
NCT02804893 — Videothoracoscopic (VATS) vs. Robotic Approach for Lobectomy or Anatomical Segmentectomy · NA · unknown

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04009915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04009915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing